GLP-1s and PCOS: separating real benefits from TikTok hype

What did @itssarahmc actually say?

Sarah posted a personal update about her experience on a GLP-1 medication, saying it curves her appetite "better than anything else I've tried." She also went a step further, claiming GLP-1 drugs have shown promise in studies related to Parkinson's and Alzheimer's disease. She repeated several times she's not a doctor, which is fair enough, but the neurological claims deserve a closer look regardless of who's making them.

Her core points: the drug suppresses appetite effectively, promotes healthy weight loss, and may have protective effects on the brain. That's a lot of ground to cover in a short video, and the accuracy varies significantly depending on which claim you're examining.

Does the science back this up?

On appetite suppression, yes, the evidence is strong. On the neurological claims, it's genuinely interesting early-stage research, but calling it established is a stretch.

GLP-1 receptor agonists like semaglutide work by mimicking a gut hormone that signals fullness to the brain. Clinical trials, including the STEP trials for semaglutide (Wilding et al., 2021, New England Journal of Medicine), consistently show significant reductions in appetite and body weight. That part of Sarah's experience tracks with what the data shows.

The Parkinson's angle is where things get more complicated. There is genuine scientific interest here. A randomized controlled trial by Athauda et al. (2017, The Lancet) found that liraglutide, a GLP-1 drug, showed potential neuroprotective effects in Parkinson's patients over 12 months. More recently, a large observational study by Holmberg et al. (2023, BMJ) found that people with type 2 diabetes using GLP-1 receptor agonists had a lower incidence of Parkinson's disease. For Alzheimer's, similar early signals exist, but no Phase 3 trial has confirmed a clinical benefit in humans yet. Saying GLP-1 drugs "have shown signs" is technically defensible. Saying they help "in the fight" against Parkinson's implies more than the research currently supports.

What did they get wrong (or right)?

Sarah gets credit for the appetite suppression claim. That is one of the most replicated findings in metabolic medicine right now, and her personal experience reflects what large trials show.

Where she stumbles is framing the neurological research as a confirmed benefit. Saying it "promotes healthy weight loss" is fine. But bundling Parkinson's and Alzheimer's into the same enthusiastic pitch, without noting these are preliminary findings in early-stage or observational studies, does viewers a disservice.

• The Parkinson's data is promising but not conclusive. Observational studies show association, not causation.
• The Alzheimer's research is even earlier stage. A Phase 2 trial of liraglutide (Femminella et al., 2019, Journal of Clinical Investigation) showed some metabolic changes in the brain, but no significant cognitive improvement.
• There are no approved indications for any GLP-1 drug in treating Parkinson's or Alzheimer's as of 2024.

Saying "studies show it helps in the fight against Parkinson's" without that context is misleading, even if the underlying papers exist. Intent doesn't change the impression a viewer takes away.

What should you actually know?

GLP-1 receptor agonists are legitimate, FDA-approved medications for type 2 diabetes and chronic weight management. The appetite suppression effects are real and well-documented. The neurological research is real too, but it is not at a stage where anyone should start or continue a GLP-1 medication expecting brain protection.

A few things worth knowing before taking anything from a video like this:

• GLP-1 drugs come with side effects, including nausea, vomiting, gastroparesis risk, and potential thyroid concerns. None of that came up here.
• These are prescription medications. Whether they're right for you depends on your health history, current medications, and a conversation with a licensed provider.
• The PCOS connection in her hashtags is worth noting separately. There is emerging research on GLP-1 drugs and PCOS symptom management, but that was not what she discussed.
• Enthusiasm about a medication you're taking is understandable. But 20,000 people watching a TikTok may not have the same health profile, and "I love it" is not a clinical recommendation.

Sarah is upfront that she's not a doctor. That disclaimer is real, but it doesn't fully offset claims that sound more settled than the research actually is.